Accessibility Menu
Alaunos Therapeutics Stock Quote

Alaunos Therapeutics (NASDAQ: TCRT)

$2.64
(-4.6%)
-0.13
Price as of October 22, 2025, 10:08 a.m. ET

KEY DATA POINTS

Current Price
$2.64
Daily Change
(-4.6%) $0.13
Day's Range
$2.58 - $2.67
Previous Close
$2.77
Open
$2.58
Beta
1.43
Volume
26,941
Average Volume
513,764
Market Cap
6.1M
Market Cap / Employee
$2.77M
52wk Range
$1.31 - $6.2
Revenue
-
Gross Margin
-39.67%
Dividend Yield
N/A
EPS
-$2.46
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Alaunos Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TCRT+28.24%-99.19%-61.8%-99%
S&P+15.06%+95.03%+14.29%+454%

Alaunos Therapeutics Company Info

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M-100.0%
Gross Profit$0.00M-100.0%
Gross Margin75.00%0.0%
Market Cap$9.59M-91.4%
Market Cap / Employee$9.59M0.0%
Employees10.0%
Net Income-$1.05M6.9%
EBITDA-$1.04M10.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$2.88M16.9%
Accounts Receivable$0.00M-50.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-84.84%32.5%
Return On Invested Capital-207.79%-21.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$0.70M58.3%
Operating Free Cash Flow-$0.70M58.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.371.121.147.34214.59%
Price to Sales859.34338.93235.381355.05-27.36%
Price to Tangible Book Value1.371.121.147.34214.59%
Enterprise Value to EBITDA-3.02-2.59-1.86-5.05-32.55%
Return on Equity-141.7%-111.8%-139.1%-107.5%-28.60%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.